Clinical Trial Update: BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP. [Phase 3]

View source ↗

Summary

Phase 3 trial update shows BF2.649 investigated in obstructive sleep apnea patients with excessive daytime sleepiness who refuse CPAP; the study status is compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Excessive Daytime Sleepiness
• Obstructive Sleep Apnea

Drugs mentioned

• BF2.649 (BF2.649)

Snippet

Sponsor: Bioprojet | Conditions: Obstructive Sleep Apnea, Excessive Daytime Sleepiness | Phase 3 | Status: COMPLETED